Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis After Positive Phase 1 Results

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced the completion of phase 1 clinical studies for LUCID-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis (MS). The therapy demonstrated a favorable safety profile and was generally well tolerated among healthy volunteers, marking a critical step toward addressing a significant unmet need in MS treatment.

Multiple sclerosis affects more than 2.8 million people worldwide and approximately 1 million in the United States. It is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include loss of mobility and control of the body. Despite the availability of numerous immune-modulating therapies, many patients continue to experience worsening disability because current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression.

Quantum BioPharma’s LUCID-MS program is built around this unmet need for therapies capable of directly protecting or restoring myelin integrity. In April 2026, the company reached a significant milestone when it announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS. The positive phase 1 results provide a foundation for advancing the therapy into later-stage clinical trials.

The company’s progress is particularly important given the progressive nature of MS, its unpredictable course, and the lack of a cure. LUCID-MS aims to address the loss of mobility and function by targeting demyelination, a key driver of disability. If successful, it could offer a new treatment paradigm for patients who have limited options beyond symptomatic management.

For more information on Quantum BioPharma’s latest news and updates, visit the company’s newsroom at https://ibn.fm/QNTM.